Abstract

Objectives: Liver cancer is one of the five most common cancer and the second leading cause of cancer death in men worldwide and the seventh most common cancer and the sixth leading cause of death in women from cancers. Liver cancer was the tenth most common cancer in Yazd in 1388 to 19% in women and 26% of males that has been more prevalent than in other provincial capitals. Methods: This cross-sectional descriptive study is a census of patients with hepatocellular carcinoma who referred to Yazd hospital pathology centers. All samples that have complete data from 1390 to 1394 were enrolled in the study. Information including age, sex, method of treatment and numbers of patients collected and then analyzed using statistical software spss 16 is placed. The aim of this study was to determine the survival rate of liver cancer patients according to age, sex, treatment, race and disease risk factors. Results: Of the 48 patients, 47.9% were female and 52.1% male during the five years . the average of age in this study was 62.81years. of the patients studied was 62.81 years .93.8% of patients were Iranian race. In this study, median survival was 7.43 months. The diabetes melitus with a prevalence of 18.8% was most common among the risk factors. alcohol consumption and the prevalence of hepatitis C has the lowest prevalence that was 1.9%. 83% of patients in this study were treated but other don’t come satisfaction for any treatment. Conclusion: In this study, like other studies, the incidence of liver cancer in men was higher than women. Most were Iranian people and the relationship between race and survival was no significant relationship between age, type of treatment, such as surgery, radiotherapy or chemotherapy with survival rate was not significant. But after Cox regression between age, family history of liver cancer, diabetes and treatment with survival in patients with hepatocellular carcinoma, there was a significant relationship. Keywords: HCC, Yazd, Survival

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call